| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca0feec348a27a7076c07ca3d4742493
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a600f12af2d0ebde6661fc46ab24bcc4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2174dd7ac8f6855b2b6a2019d2e222ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f14c97f0f8acd610dd23e1ede025e99a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0eff49f940720b51169cb9d9bde8c5ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5c29324a5cd3d6b8a38acff0801c815 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-50 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1131 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713 |
| filingDate |
2008-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5985918b065bf5b58c6a86f989a01387
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b204fca3317fa52e3415d37c961a4353
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab7c76003c366e14cc3ec7c4371081d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bbc3f465224b72bd42fdb39839fdffcc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5ac345a97b2b7b1b160f5b1650e06b2 |
| publicationDate |
2010-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2008146251-A9 |
| titleOfInvention |
A primary micro rna expression cassette |
| abstract |
This invention relates to inhibition of hepatitis gene expression. More specifically, the invention relates to a method of using RNA sequences to inhibit Hepatitis B and C Virus replication. Expression cassettes that include DNA sequences derived from endogenous micro RNAs (miRs) are used in the method and are transcribed by Pol Il promoters, and then processed to generate sequences that are specific to target hepatitis virus sequences (RNAi effecter sequences). The RNAi effecter sequences can target the selected hepatitis virus sequences resulting in gene silencing or transcriptional inhibition of the hepatitis virus gene. The expression cassettes may be delivered in vitro or in vivo to host cells. A pharmaceutical composition containing the expression cassettes is also claimed. |
| priorityDate |
2007-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |